Ho Jin Yi

Ho Jin Yi

Auto-generated profile, based on publicly available information

Ho Jin Yi

College of Pharmacy, Graduate School of Applied Science and Technology for Skin Health and Aesthetics, Ewha Womans University, Seoul, 120-750, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2024 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
JPJiyoung Park
Jiyoung Park
JSJuhyun Sim
Juhyun Sim
HYHo Jin Yi
Ho Jin Yi
SRSue Goo Rhee
Sue Goo Rhee
HWHyun Ae Woo
Hyun Ae Woo
In this study, we investigated the potential role of PrxI in cis-diamminedichloroplatinum (cisplatin)-induced renal damage in mice. The anticancer drug cisplatin is a chemotherapeutic agent that is widely used to treat solid tumors. Cisplatin-induced nephrotoxicity is a serious dose-limiting side effect, primarily caused by oxidative stress. The oxidative stress further damages DNA, membranes, and mitochondria, and increases endoplasmic reticulum (ER) stress. Cisplatin produces reactive oxygen species (ROS) through Cytochrome P450 2E1 (CYP2E1) and localizes to the surface of the ER, where CYP2E1 is located. Among the six Prx isoforms, Prx I was selectively degraded in cisplatin-treated kidneys during severe renal function damage. Prx I degradation is blocked in mouse proximal tubular cells treated with 3-methyladenine, an autophagy inhibitor, and in MEF lacking ATG7. Moreover, increased ROS levels on the ER surface due to CYP2E1 overexpression further accelerated Prx I degradation. These results suggest that Prx I degradation is largely mediated through autophagy, which is promoted by cisplatin-induced ER stress. Ablation of Prx I exacerbated cisplatin-induced nephrotoxicity and significantly increased the abundance of oxidative stress, ER stress, and inflammatory markers in the kidney, indicating that Prx I plays a protective role against cisplatin-induced nephrotoxicity.

17 April 2026 in Redox Biology
Verified
Journal Article
Open access
JPJi Won Park
Ji Won Park
SJSe Yeon Jang
Se Yeon Jang
MKMi Yeon Kim
Mi Yeon Kim
HYHo Jin Yi
Ho Jin Yi
SSSeong Keun Sonn
Seong Keun Sonn
TCTONG-SHIN CHANG
TONG-SHIN CHANG
Doxorubicin (DOX) is a widely used anticancer drug associated with severe cardiotoxicity primarily driven by mitochondrial dysfunction and reactive oxygen species (ROS) production. Hydrogen peroxide (H2O2), a major mitochondrial ROS, significantly contributes to cardiotoxicity, yet its precise mechanistic role in DOX-induced cardiotoxicity remains incompletely understood. Here, we investigated the critical role of mitochondrial H2O2 in DOX-induced cardiotoxicity using rat cardiomyocyte H9c2 cells with stable knockdown or reconstitution of mitochondrial antioxidant enzyme peroxiredoxin Ⅲ (PrxⅢ), which specifically regulates mitochondrial H2O2 levels. Our results demonstrated that severe mitochondrial H2O2 accumulation (>10-fold compared to control) in PrxⅢ-depleted cells exacerbated mitochondrial oxidative stress, evidenced by increased cardiolipin oxidation and mitochondrial membrane potential dissipation. Furthermore, excessive mitochondrial H2O2 impaired mitochondrial fusion by reducing fusion-related protein expression, disrupted autophagic flux via lysosomal dysfunction, and significantly attenuated mitophagy, ultimately leading to enhanced apoptosis. Conversely, moderate mitochondrial H2O2 levels (5- to 8-fold increase compared to control) observed in PrxⅢ-expressing cells promoted mitochondrial elongation, enhanced mitophagy, and preserved autophagic flux, suggesting a protective adaptation against DOX-induced oxidative stress. In vivo experiments using PrxⅢ knockout mice confirmed that loss of PrxⅢ aggravated DOX-induced cardiac dysfunction. Bioinformatic analysis of independent public transcriptome datasets and targeted qPCR validation in PrxⅢ-deficient cardiac tissues further confirmed that the mitochondrial quality control pathways identified in vitro are robustly dysregulated in vivo. Additionally, PrxⅢ deficiency markedly increased mitochondrial structural damage without significantly affecting cardiac fibrosis or hypertrophy. Notably, mitigating the mitochondrial H2O2 burden and protecting the mitochondrial inner membrane using the mitochondria-targeted antioxidant peptide SS-31 successfully rescued this exacerbated cardiac dysfunction. In conclusion, our findings establish mitochondrial H2O2 as a pivotal determinant in DOX-induced mitochondrial dysfunction and cardiotoxicity, highlighting PrxⅢ as a promising therapeutic target for mitigating oxidative cardiac injury.